ロード中...
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE) invited Teva, the company manufacturing arsenic trioxide (ATO; tradename Trisenox(®)), to submit evidence for the clinical and cost effectiveness of ATO for untreated and relapsed or refractory acute promyelocytic leukaemia (APL). Kleijnen...
保存先:
| 出版年: | Pharmacoeconomics |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6559128/ https://ncbi.nlm.nih.gov/pubmed/30426463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0738-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|